Literature DB >> 2487713

Common problems experienced by adults with osteoarthritis.

M Weinberger, W M Tierney, P Booher.   

Abstract

Functional status and noncompliance were assessed at baseline in 327 patients with osteoarthritis (OA), 96% of whom were interviewed again later either by telephone or at their next scheduled primary care visit. One-third of the sample reported noncompliance at baseline. During the follow-up interviews, commonly identified problems included having an inadequate supply of medicines to last until their next physician visit (47%), experiencing gastrointestinal complaints (36%), and reporting barriers to primary care (32%). For OA patients with hypertension or heart disease (N = 241), 75% reported clinically important symptoms. Patients with poorer functional status at baseline generally reported more subsequent problems. We conclude that patients frequently have correctable problems (e.g., medication noncompliance and side effects, barriers to care). These patients may be identified prospectively by their poor functional status. Arthritis health care professionals may wish to consider patient-oriented interventions to obviate these problems when evaluating functional status.

Entities:  

Mesh:

Year:  1989        PMID: 2487713     DOI: 10.1002/anr.1790020304

Source DB:  PubMed          Journal:  Arthritis Care Res        ISSN: 0893-7524


  2 in total

1.  Systolic and pulse pressure associate with incident knee osteoarthritis: data from the Osteoarthritis Initiative.

Authors:  Grace H Lo; Timothy E McAlindon; Jeffrey N Katz; Jeffrey B Driban; Lori Lyn Price; Charles B Eaton; Nancy J Petersen; Christie M Ballantyne; Maria E Suarez-Almazor
Journal:  Clin Rheumatol       Date:  2017-06-01       Impact factor: 2.980

2.  Hypoxia modulates the phenotype of osteoblasts isolated from knee osteoarthritis patients, leading to undermineralized bone nodule formation.

Authors:  Joan Chang; Sonya G Jackson; John Wardale; Simon W Jones
Journal:  Arthritis Rheumatol       Date:  2014-07       Impact factor: 10.995

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.